3/20
04:32 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.
3/14
02:25 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1.00 to $0.75. They now have a "sell" rating on the stock.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1.00 to $0.75. They now have a "sell" rating on the stock.
3/13
07:00 am
mcrb
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
High
Report
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
3/6
11:08 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/4
02:19 pm
mcrb
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight [Yahoo! Finance]
Low
Report
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight [Yahoo! Finance]
3/4
07:07 am
mcrb
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 [Yahoo! Finance]
High
Report
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 [Yahoo! Finance]
3/4
07:00 am
mcrb
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
High
Report
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
3/3
07:42 am
mcrb
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach [Yahoo! Finance]
Low
Report
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach [Yahoo! Finance]
3/3
07:00 am
mcrb
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
Low
Report
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
2/25
11:05 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/14
10:01 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
1/16
07:00 am
mcrb
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
High
Report
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
1/11
02:09 am
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
1/9
07:00 am
mcrb
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Low
Report
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
1/3
11:08 pm
mcrb
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
12/28
03:08 pm
mcrb
Building Life With Generative AI [Forbes]
Medium
Report
Building Life With Generative AI [Forbes]